Symbols / PRAX
PRAX Chart
About
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.64B |
| Enterprise Value | 8.95B | Income | -303.27M | Sales | — |
| Book/sh | 34.85 | Cash/sh | 21.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 168 | IPO | — |
| P/E | — | Forward P/E | -39.99 | PEG | — |
| P/S | — | P/B | 9.97 | P/C | — |
| EV/EBITDA | -27.43 | EV/Sales | — | Quick Ratio | 10.03 |
| Current Ratio | 10.22 | Debt/Eq | 0.01 | LT Debt/Eq | — |
| EPS (ttm) | -12.99 | EPS next Y | -8.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-30 | ROA | -28.69% |
| ROE | -45.83% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 27.74M |
| Shs Float | 25.78M | Short Float | 13.93% | Short Ratio | 6.44 |
| Short Interest | — | 52W High | 354.43 | 52W Low | 26.70 |
| Beta | 2.90 | Avg Volume | 688.94K | Volume | 322.55K |
| Target Price | $600.71 | Recom | Strong_buy | Prev Close | $342.71 |
| Price | $347.55 | Change | 1.41% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$600.71
Mean price target
2. Current target
$345.00
Latest analyst target
3. DCF / Fair value
$-94.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$345.00
Low
$130.00
High
$1245.00
Mean
$600.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Outperform | $500 |
| 2026-02-20 | main | Wells Fargo | Equal-Weight → Equal-Weight | $305 |
| 2026-02-20 | main | Baird | Outperform → Outperform | $433 |
| 2026-02-20 | main | Truist Securities | Buy → Buy | $700 |
| 2026-02-20 | main | Wedbush | Underperform → Underperform | $130 |
| 2026-02-10 | main | Guggenheim | Buy → Buy | $800 |
| 2026-02-04 | main | Needham | Buy → Buy | $510 |
| 2026-02-02 | init | Wells Fargo | — → Equal-Weight | $282 |
| 2026-01-30 | main | HC Wainwright & Co. | Buy → Buy | $1245 |
| 2026-01-28 | main | Piper Sandler | Overweight → Overweight | $1200 |
| 2026-01-12 | main | Wedbush | Underperform → Underperform | $95 |
| 2025-12-29 | main | BTIG | Buy → Buy | $843 |
| 2025-12-15 | main | Oppenheimer | Outperform → Outperform | $750 |
| 2025-12-09 | main | Jefferies | Buy → Buy | $450 |
| 2025-12-09 | main | Guggenheim | Buy → Buy | $760 |
| 2025-12-08 | main | TD Cowen | Buy → Buy | $353 |
| 2025-12-08 | main | Truist Securities | Buy → Buy | $500 |
| 2025-12-08 | main | Needham | Buy → Buy | $315 |
| 2025-12-08 | reit | HC Wainwright & Co. | Buy → Buy | $340 |
| 2025-12-08 | main | BTIG | Buy → Buy | $507 |
- Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum - simplywall.st ue, 24 Feb 2026 18
- Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - Yahoo Finance Mon, 23 Feb 2026 18
- Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - The Motley Fool Mon, 23 Feb 2026 18
- Praxis lines up 4 brain drugs with $20B revenue potential - Stock Titan hu, 19 Feb 2026 12
- PRAX Stock: Wells Fargo Raises Price Target to $305 | PRAX Stock News - GuruFocus Fri, 20 Feb 2026 18
- Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga Fri, 20 Feb 2026 17
- $PRAX ($PRAX) Releases Q4 2025 Earnings - Quiver Quantitative hu, 19 Feb 2026 12
- Praxis Precision Medicines stock reaches 52-week high at 337.01 USD - Investing.com Fri, 20 Feb 2026 18
- PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Zacks Investment Research Mon, 08 Dec 2025 08
- A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum - Yahoo Finance ue, 24 Feb 2026 12
- Wolfe Research Initiates Coverage of Praxis Precision Medicines (PRAX) with Outperform Recommendation - Nasdaq ue, 24 Feb 2026 12
- Wolfe Research Initiates Coverage on Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus ue, 24 Feb 2026 12
- Wolfe Research initiates Praxis stock with outperform rating - Investing.com Nigeria ue, 24 Feb 2026 16
- Praxis Precision Medicines Nears First Neurology Launches With Dual NDA Filings - simplywall.st Mon, 23 Feb 2026 23
- Praxis Precision Medicines Submits NDAs for Ulixacaltamide and Relutrigine, Anticipates Growth into 2026 - Quiver Quantitative hu, 19 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1166 | — | — | Stock Award(Grant) at price 0.00 per share. | KINDLER JEFFREY B | Director | — | 2026-02-06 00:00:00 | D |
| 1 | 1166 | — | — | Stock Award(Grant) at price 0.00 per share. | ARBUCKLE STUART A | Director | — | 2026-02-06 00:00:00 | D |
| 2 | 27640 | — | — | Stock Award(Grant) at price 0.00 per share. | SOUZA MARCIO SILVA DE | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 9625 | — | — | Stock Award(Grant) at price 0.00 per share. | SNIECINSKI MEGAN | Chief Operating Officer | — | 2026-01-08 00:00:00 | D |
| 4 | 3750 | — | — | Stock Award(Grant) at price 0.00 per share. | MASTROCOLA LAUREN | Officer | — | 2026-01-08 00:00:00 | D |
| 5 | 6875 | — | — | Stock Award(Grant) at price 0.00 per share. | NEMIROFF ALEX | General Counsel | — | 2026-01-08 00:00:00 | D |
| 6 | 8800 | — | — | Stock Award(Grant) at price 0.00 per share. | KELLY TIMOTHY EDWIN | Chief Financial Officer | — | 2026-01-08 00:00:00 | D |
| 7 | 400 | — | — | Stock Gift at price 0.00 per share. | SOUZA MARCIO SILVA DE | Chief Executive Officer | — | 2025-12-30 00:00:00 | I |
| 8 | 13600 | 831257 | — | Conversion of Exercise of derivative security at price 43.37 - 133.65 per share. | MASTROCOLA LAUREN | Officer | — | 2025-11-20 00:00:00 | D |
| 9 | 25130 | 1853531 | — | Conversion of Exercise of derivative security at price 44.40 - 133.65 per share. | NEMIROFF ALEX | General Counsel | — | 2025-11-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -199.81M | -125.94M | -214.57M | -167.15M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -182.82M | -123.28M | -214.03M | -167.06M |
| ReconciledDepreciation | 358.00K | 432.00K | 419.00K | 182.00K |
| EBITDA | -199.81M | -125.94M | -214.57M | -167.15M |
| EBIT | -200.16M | -126.37M | -214.99M | -167.33M |
| NormalizedIncome | -182.82M | -123.28M | -214.03M | -167.06M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -182.82M | -123.28M | -214.03M | -167.06M |
| TotalExpenses | 208.72M | 128.82M | 214.99M | 167.33M |
| TotalOperatingIncomeAsReported | -200.16M | -126.37M | -214.99M | -167.33M |
| DilutedAverageShares | 17.91M | 6.59M | 3.07M | 2.83M |
| BasicAverageShares | 17.91M | 6.59M | 3.07M | 2.83M |
| DilutedEPS | -10.21 | -18.69 | -69.60 | -59.10 |
| BasicEPS | -10.21 | -18.69 | -69.60 | -59.10 |
| DilutedNIAvailtoComStockholders | -182.82M | -123.28M | -214.03M | -167.06M |
| NetIncomeCommonStockholders | -182.82M | -123.28M | -214.03M | -167.06M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -182.82M | -123.28M | -214.03M | -167.06M |
| NetIncomeIncludingNoncontrollingInterests | -182.82M | -123.28M | -214.03M | -167.06M |
| NetIncomeContinuousOperations | -182.82M | -123.28M | -214.03M | -167.06M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -182.82M | -123.28M | -214.03M | -167.06M |
| OtherIncomeExpense | 17.35M | 3.10M | 957.00K | 271.00K |
| OtherNonOperatingIncomeExpenses | 17.35M | 3.10M | 957.00K | 271.00K |
| OperatingIncome | -200.16M | -126.37M | -214.99M | -167.33M |
| OperatingExpense | 208.72M | 128.82M | 214.99M | 167.33M |
| ResearchAndDevelopment | 152.41M | 86.77M | 155.04M | 120.26M |
| SellingGeneralAndAdministration | 56.30M | 42.05M | 59.95M | 47.08M |
| GeneralAndAdministrativeExpense | 56.30M | 42.05M | 59.95M | 47.08M |
| OtherGandA | 56.30M | 42.05M | 59.95M | 47.08M |
| TotalRevenue | 8.55M | 2.45M | 0.00 | 0.00 |
| OperatingRevenue | 8.55M | 2.45M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 19.42M | 8.79M | 3.29M | 3.02M |
| ShareIssued | 19.42M | 8.79M | 3.29M | 3.02M |
| TotalDebt | 1.37M | 2.50M | 3.50M | 4.31M |
| TangibleBookValue | 445.45M | 69.67M | 76.11M | 250.81M |
| InvestedCapital | 445.45M | 69.67M | 76.11M | 250.81M |
| WorkingCapital | 366.82M | 69.13M | 76.50M | 248.97M |
| NetTangibleAssets | 445.45M | 69.67M | 76.11M | 250.81M |
| CapitalLeaseObligations | 1.37M | 2.50M | 3.50M | 4.31M |
| CommonStockEquity | 445.45M | 69.67M | 76.11M | 250.81M |
| TotalCapitalization | 445.45M | 69.67M | 76.11M | 250.81M |
| TotalEquityGrossMinorityInterest | 445.45M | 69.67M | 76.11M | 250.81M |
| StockholdersEquity | 445.45M | 69.67M | 76.11M | 250.81M |
| GainsLossesNotAffectingRetainedEarnings | 654.00K | 0.00 | -173.00K | -176.00K |
| OtherEquityAdjustments | 654.00K | -173.00K | -176.00K | |
| RetainedEarnings | -836.74M | -653.92M | -530.64M | -316.62M |
| AdditionalPaidInCapital | 1.28B | 723.58M | 606.92M | 567.60M |
| CapitalStock | 14.00K | 13.00K | 5.00K | 5.00K |
| CommonStock | 14.00K | 13.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 37.66M | 18.28M | 39.02M | 41.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 110.00K | 2.53M | 4.68M | 3.50M |
| NonCurrentDeferredLiabilities | 0.00 | 1.16M | 2.18M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 1.16M | 2.18M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 110.00K | 1.37M | 2.50M | 3.50M |
| LongTermCapitalLeaseObligation | 110.00K | 1.37M | 2.50M | 3.50M |
| CurrentLiabilities | 37.55M | 15.75M | 34.34M | 38.43M |
| CurrentDeferredLiabilities | 0.00 | 1.39M | 2.82M | 0.00 |
| CurrentDeferredRevenue | 0.00 | 1.39M | 2.82M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 1.26M | 1.13M | 1.00M | 810.00K |
| CurrentCapitalLeaseObligation | 1.26M | 1.13M | 1.00M | 810.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.37M | 3.72M | 2.80M | 7.18M |
| PayablesAndAccruedExpenses | 26.93M | 9.52M | 27.72M | 30.44M |
| CurrentAccruedExpenses | 14.40M | 3.70M | 13.05M | 19.66M |
| Payables | 12.53M | 5.82M | 14.67M | 10.78M |
| AccountsPayable | 12.53M | 5.82M | 14.67M | 10.78M |
| TotalAssets | 483.11M | 87.95M | 115.13M | 292.75M |
| TotalNonCurrentAssets | 78.74M | 3.07M | 4.29M | 5.34M |
| OtherNonCurrentAssets | 416.00K | 416.00K | 416.00K | 472.00K |
| InvestmentsAndAdvances | 76.96M | 0.00 | ||
| InvestmentinFinancialAssets | 76.96M | 0.00 | ||
| AvailableForSaleSecurities | 76.96M | |||
| NetPPE | 1.36M | 2.65M | 3.87M | 4.87M |
| AccumulatedDepreciation | -1.36M | -1.00M | -572.00K | -153.00K |
| GrossPPE | 2.72M | 3.66M | 4.44M | 5.02M |
| OtherProperties | 359.00K | 359.00K | 309.00K | 242.00K |
| MachineryFurnitureEquipment | 1.23M | 1.23M | 1.23M | 1.12M |
| BuildingsAndImprovements | 1.13M | 2.06M | 2.90M | 3.65M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 404.37M | 84.88M | 110.84M | 287.41M |
| OtherCurrentAssets | 11.80M | 3.58M | 10.35M | 11.50M |
| PrepaidAssets | 10.35M | 11.50M | ||
| CashCashEquivalentsAndShortTermInvestments | 392.57M | 81.30M | 100.49M | 275.91M |
| OtherShortTermInvestments | 177.19M | 0.00 | 38.87M | 137.21M |
| CashAndCashEquivalents | 215.37M | 81.30M | 61.62M | 138.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -131.76M | -111.19M | -185.49M | -125.60M |
| RepurchaseOfCapitalStock | 0.00 | |||
| IssuanceOfCapitalStock | 512.00M | 91.59M | 9.56M | 105.71M |
| CapitalExpenditure | -50.00K | -444.00K | -1.05M | |
| EndCashPosition | 215.79M | 81.72M | 62.03M | 139.72M |
| BeginningCashPosition | 81.72M | 62.03M | 139.72M | 297.21M |
| ChangesInCash | 134.07M | 19.68M | -77.69M | -157.49M |
| FinancingCashFlow | 514.32M | 91.87M | 10.46M | 107.59M |
| CashFlowFromContinuingFinancingActivities | 514.32M | 91.87M | 10.46M | 107.59M |
| NetOtherFinancingCharges | -308.00K | -137.00K | -522.00K | -575.00K |
| ProceedsFromStockOptionExercised | 2.63M | 416.00K | 1.43M | 2.45M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockPayments | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 512.00M | 91.59M | 9.56M | 105.71M |
| CommonStockIssuance | 512.00M | 91.59M | 9.56M | 105.71M |
| InvestingCashFlow | -248.49M | 38.95M | 96.89M | -140.52M |
| CashFlowFromContinuingInvestingActivities | -248.49M | 38.95M | 96.89M | -140.52M |
| NetInvestmentPurchaseAndSale | -248.49M | 39.00M | 97.33M | -139.47M |
| SaleOfInvestment | 123.03M | 39.00M | 180.35M | 24.70M |
| PurchaseOfInvestment | -371.52M | 0.00 | -83.02M | -164.17M |
| NetPPEPurchaseAndSale | 0.00 | -50.00K | -444.00K | -1.05M |
| PurchaseOfPPE | 0.00 | -50.00K | -444.00K | -1.05M |
| OperatingCashFlow | -131.76M | -111.14M | -185.04M | -124.55M |
| CashFlowFromContinuingOperatingActivities | -131.76M | -111.14M | -185.04M | -124.55M |
| ChangeInWorkingCapital | 10.92M | -14.03M | -1.78M | 16.13M |
| ChangeInOtherWorkingCapital | -2.55M | -2.45M | 5.06M | -41.00K |
| ChangeInOtherCurrentLiabilities | -1.13M | -1.00M | -811.00K | -763.00K |
| ChangeInPayablesAndAccruedExpense | 22.82M | -17.35M | -6.57M | 22.72M |
| ChangeInAccruedExpense | 16.11M | -8.50M | -10.46M | 15.45M |
| ChangeInPayable | 6.71M | -8.86M | 3.89M | 7.27M |
| ChangeInAccountPayable | 6.71M | -8.86M | 3.89M | 7.27M |
| ChangeInPrepaidAssets | -8.22M | 6.77M | 547.00K | -5.78M |
| OtherNonCashItems | 3.43M | 837.00K | 752.00K | 1.41M |
| StockBasedCompensation | 41.36M | 24.86M | 28.59M | 22.69M |
| AmortizationOfSecurities | -5.01M | 47.00K | 1.00M | 2.09M |
| DepreciationAmortizationDepletion | 358.00K | 432.00K | 419.00K | 182.00K |
| DepreciationAndAmortization | 358.00K | 432.00K | 419.00K | 182.00K |
| Depreciation | 358.00K | 432.00K | 419.00K | 182.00K |
| NetIncomeFromContinuingOperations | -182.82M | -123.28M | -214.03M | -167.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PRAX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|